Portfolio company
Deepull
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
Deepull develops automated diagnostic systems that identify pathogens and antibiotic resistance directly from blood samples for healthcare providers treating sepsis and acute infections.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Septest
This company develops point-of-need blood tests for healthcare professionals to rapidly identify infection and inflammation biomarkers in patients.
iFAST Diagnositcs
The company develops rapid antimicrobial susceptibility testing systems for hospitals and clinical laboratories to identify effective antibiotic treatments for bacterial infections.
Novus Diagnostic
Novus Diagnostics develops point-of-care diagnostic devices for clinicians to detect and classify bloodstream infections, specifically sepsis, within fifteen minutes at the bedside.
Resistell
This company develops nanomotion-based diagnostic platforms for rapid antibiotic susceptibility testing to help healthcare providers and laboratories treat bloodstream infections.
Presymptom Health
This company develops AI-driven diagnostic tests and software that detect infection and sepsis in patients for use by healthcare providers and clinical labs.
Anvil Diagnostics
This company develops molecular blood tests to identify and quantify pathogens in hospitalised patients using digital PCR hardware.
Advanced Perfusion Diagnostics
This company develops single-use devices for non-invasive, continuous microcirculation assessment and early sepsis detection for clinicians in critical care and surgical settings.
SepsiScan
This company develops bedside imaging devices for real-time microcirculation monitoring and early sepsis diagnosis for intensive care units and hospitals.
